The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates that have demonstrated the potential for enhanced activity and safety compared with currently approved drugs.
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Chimerix-To-Present-At-Two-Upcoming-Healthcare-Con/ArticleNewsFeed/Article/detail/796221?ref=25
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Chimerix-To-Present-At-Two-Upcoming-Healthcare-Con/ArticleNewsFeed/Article/detail/796221?ref=25
No comments:
Post a Comment